Kaplan–Meier survival analysis indicated that serous and mucinous ovarian cancer patients with high JMJD6 expression had a significantly shorter median overall survival as well as disease-free survival (p = 0.0002, p = 0.0087, p < 0.0001, and p < 0.0001, respectively, Fig. 1b–e). This evidence concerns the gene JMJD6 and mucinous ovarian cancer.